February 23, 2021
Scientists at University of California San Diego School of Medicine validated a more inclusive and comprehensive genetic tool, known as a polygenic hazard score (PHS), for predicting age of onset of aggressive prostate cancer.
July 17, 2012
…a genetic test to predict a man’s risk for prostate cancer. Use of the test could reduce the need for repeat biopsies in men who have had a negative biopsy.
October 31, 2022
Researchers at UC San Diego report that a polygenic hazard score based on 290 genetic variants could be an effective tool for predicting genetic risk of lethal prostate cancer, which kills more than 34,000 men in the U.S. annually.
May 6, 2019
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.
March 31, 2015
By age 60, more than 50 percent of men in the United States suffer from benign prostatic hyperplasia (BPH), a condition that leads to annoying changes in urinary flow. While medical therapy is usually the first line of treatment, a new minimally invasive implant can dramatically reduce symptoms for men.
October 5, 2022
UC San Diego Health is the first hospital system in the region to offer a novel treatment option for patients with prostate cancer that has spread throughout the body and has not responded to other therapeutics.
November 3, 2020
Researchers with UC San Diego School of Medicine and Moores Cancer Center say active surveillance is safe for African American men with low-risk prostate cancer.
April 30, 2014
…contributions to levels of these blood lipids and to prostate cancer.
January 6, 2015
…a novel imaging technique that measurably improves upon current prostate imaging – and may have significant implications for how patients with prostate cancer are ultimately treated.
April 27, 2016
…a new model of care for patients with low-risk prostate cancer. The evidence-based approach uses best practices to appropriately select and follow patients to avoid disease overtreatment. Results of the three-year study are now published online in the journal of Urology.
